The FDA’s Office of Prescription Drug Promotion (OPDP) sent an Untitled Letter to Mayne Pharma LLC in Raleigh, N.C., alleging a speaker deck for Nextstellis (drospirenone and estetrol tablets) contained “false or misleading claims” about product risks. The April 28 Untitled Letter was the result of a requested FDA review of a promotional communication. As has been the case in... Read More